20/20 Biolabs Inc. cash flow to debt ratio of -149.51% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

20/20 Biolabs Inc.'s free cash flow has decreased 73.77K% from $-2.60M last year to $-1.92B, signaling decreasing performance

20/20 Biolabs Inc.'s debt to equity ratio is 0.34, which means that the company's assets are healthy financed, signaling financial stability.

20/20 Biolabs Inc.'s debt has decreased relative to shareholder equity from 0.99 last year to 0.34 today, signaling strengthened financials

20/20 Biolabs Inc. has negative EBITDA, making leverage ratio unreliable

20/20 Biolabs Inc.'s interest coverage ratio of 28.06 indicates that earnings with good margin can cover interest payments on company debt

20/20 Biolabs Inc.'s profit margin has decreased (3.83%) in the last year from -316.81% to -328.96%, signaling decreasing performance

20/20 Biolabs Inc.'s short-term liabilities of $2.46B exceed its short-term assets of $1.47B, signaling financial risk

20/20 Biolabs Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

20/20 Biolabs Inc.'s return on equity of 79.00%, is higher than 15.00%, indicating good performance

20/20 Biolabs Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

20/20 Biolabs Inc. has insufficient public price history to evaluate earnings stability.

20/20 Biolabs Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

20/20 Biolabs Inc. has negative free cash flow, indicating cash burn

20/20 Biolabs Inc.'s yearly earnings has increased -32.65% since last year from $-5.55M to $-3.74M, signaling increasing performance

20/20 Biolabs Inc.'s yearly revenue has increased 116.61K% since last year from $1.75M to $2.05B, signaling increasing performance

ROIC -92.48% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

20/20 Biolabs Inc.'s 3-year revenue CAGR of -43.03% is negative, indicating declining revenue over the past 3 years

20/20 Biolabs Inc. has insufficient public price history to evaluate revenue consistency.

20/20 Biolabs Inc. has insufficient public price history to evaluate ROE consistency.

20/20 Biolabs Inc. has insufficient data to evaluate this check.

20/20 Biolabs Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

20/20 Biolabs Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

20/20 Biolabs Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

20/20 Biolabs Inc. has insufficient data to evaluate this check.

20/20 Biolabs Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

20/20 Biolabs Inc. has a price-to-book ratio of 1.27x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

20/20 Biolabs Inc. has a price-to-sales ratio of 2.67x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue